Livagen 20mg
Liver Tissue Peptide Bioregulator for Hepatic Research
Livagen is a Khavinson tetrapeptide bioregulator targeting hepatic tissue, normalizing liver cell gene expression to support hepatocyte function and liver health in research models.
Liver Tissue Peptide Bioregulator for Hepatic Research
Liver-specific peptide bioregulator modulating hepatocyte gene expression for liver tissue homeostasis, supporting liver regeneration and function in aging and injury research.
As one of the most studied compounds in the recovery & healing research space, Livagen has attracted sustained scientific interest across Liver health research, Hepatic regeneration studies. Peer-reviewed evidence indicates that liver-specific Khavinson bioregulator, which has positioned Livagen as a reference standard for researchers exploring liver health research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
Livagen Documented Benefits: 1 Documented Mechanisms
Hepatic Support
Normalizes hepatocyte gene expression for liver tissue health and regeneration.
How Livagen Works: Molecular Mechanism & Pathway
Liver tissue-specific short peptide bioregulator modulating epigenetic gene expression in hepatocytes.
The 1 primary research pathways identified for Livagen — Hepatic Support — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that hepatocyte gene expression normalization, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, Livagen's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
Livagen is routinely studied alongside NAD+ and Glutathione in recovery & healing-focused compound panels. Researchers investigating liver health research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that 20mg research format has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All Livagen research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- Liver-specific Khavinson bioregulator
- Hepatocyte gene expression normalization
- 20mg research format
Ideal For
- Liver health research
- Hepatic regeneration studies
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on Livagen. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
Liver-specific Khavinson bioregulator
Hepatocyte gene expression normalization
20mg research format
Third-Party Verified Every Batch
Each vial of Livagen is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
